Inovio says the FDA lifted its ‘hold’ on the Phase 3 clinical trial for its COVID-19 shot

0
90

Shares of Inovio Pharmaceuticals Inc. INO, +0.75% gained 5.9% in premarket trading on Tuesday after the company said it can move forward with the Phase 3 clinical trial for its experimental COVID-19 shot now that the Food and Drug Administration has lifted its partial clinical hold. Inovio had announced the partial clinical hold in September of last year. Inovio’s stock is down 23.8% this year, while the S&P 500 SPX, +0.09% is up 25.2%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleDeep Dive: A bargain you can’t ignore: Small-cap stocks are trading at their second-biggest discount in 20 years
Next articleU.S. producer price index rises 0.6% in October, matching economists’ forecast

LEAVE A REPLY

Please enter your comment!
Please enter your name here